Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression

Executive Summary

• Optimi Health Corp. announced the export of its GMP‑manufactured 5 mg natural psilocybin capsules to Australia under the Authorised Prescriber Scheme, marking the company’s second finished psychedelic product supplied to that program.
• The shipment expands Optimi’s portfolio in Australia, which already includes 40 mg and 60 mg MDMA capsules for PTSD treatment, and supports patients with treatment‑resistant depression (TRD).
• The export is conducted under a Health Canada Drug Establishment Licence, with treatment outcomes to be tracked via Australia’s national patient registry in partnership with the Australian National University.

Key Details

• Product: 5 mg natural psilocybin capsules (pharmaceutical‑grade, GMP‑manufactured).
• Destination: Australia – Authorised Prescriber Scheme for treatment‑resistant depression (TRD).
• Significance: Second finished drug product supplied to the Australian scheme; first psilocybin dosage form for TRD in that market.
• Existing Australian Products: 40 mg and 60 mg MDMA capsules for post‑traumatic stress disorder (PTSD).
• Regulatory Framework: Export authorized under Health Canada Drug Establishment Licence; product to be prescribed within Australia’s regulated framework.
• Reimbursement: Department of Veterans’ Affairs may fully reimburse eligible patients for the therapy, covering both medication and psychotherapy.
• Outcome Tracking: Clinical outcomes will be captured in Australia’s national patient registry through a partnership with Australian National University (ANU).
• Contact for Access Inquiries (Australia): Mind Medicine Australia – [email protected].
• Global Sales Contact: [email protected].

Notable Quotes

“Supplying pharmaceutical‑grade psilocybin outside of traditional clinical trials within a nationally regulated framework is an important milestone for our team and shareholders.” – Dane Stevens, CEO & Co‑Founder, Optimi Health Corp.